CAPR
FDA drops the homework before the big test
Capricor Therapeutics got walloped Monday after the FDA posted briefing documents ahead of the company’s July 29 advisory committee meeting. Translation: the agency basically showed its cards early, and the hand looked a lot less friendly than CAPR shareholders wanted.
Why investors are freaking out
The FDA’s docs questioned whether Capricor’s Duchenne cell therapy has enough evidence to meet the standard for approval. That matters because the company’s application leans heavily on a single pivotal Phase 3 study, HOPE-3, while the agency’s framing reminded everyone that it usually wants more than one strong, well-controlled trial.
The market heard the subtext loud and clear
That regulatory tone hit the stock like a brick. Shares were down more than 60% in premarket trading, with the market effectively saying: if the FDA is already skeptical before the advisory committee even meets, the odds of a smooth approval path just got a lot slimmer.
Big picture
For biotech investors, this is the classic reminder that a great-looking data story and an approvable data package are not always the same thing. And in regulatory land, the vibe of the briefing docs can matter almost as much as the vote itself.